Navigation Links
Insmed Announces Planned Departure Of Chief Financial Officer
Date:7/30/2012

MONMOUTH JUNCTION, N.J., July 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's Executive Vice President & Chief Financial Officer, Kevin Tully, will be leaving the Company when his current contract expires on December 1, 2012 due to family reasons.  Insmed has begun its search to identify candidates to replace Mr. Tully in the CFO role. 

"I would like to thank Kevin for his considerable contributions to Insmed in the 11 years he has spent with the Company," said Timothy Whitten, Insmed's President and Chief Executive Officer. "He was instrumental in enabling the successful combination of Insmed and Transave, as well completing a number of other critical initiatives during his tenure.  We wish him well in all his future endeavors."

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases.  Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced liposomal pulmonary technology in areas of high unmet need.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to Mr. Tully's departure and the search for his replacement constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, delays in
'/>"/>

SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Insmed to Host 2012 Second Quarter Earnings Conference Call
2. Insmed To Present At JMP Securities 7th Annual Healthcare Conference
3. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
4. Insmed Announces First Quarter 2012 Financial Results
5. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
6. Insmed to Host 2012 First Quarter Earnings Conference Call
7. Absorption Systems announces novel test platform for interactions with the BCRP transporter
8. Novogen Announces Merger Agreement With Kai Medical And Distribution Of Mei Pharma Shares
9. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
10. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
11. Gentris Corporation Announces Collaboration to Study Blood Stability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Omthera Pharmaceuticals, Inc., a privately-held emerging specialty ... and Chief Executive Officer, will present at the ... InterContinental Boston, in Boston, Massachusetts, on Wednesday, June ... About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera ...
... Alere Inc. (NYSE: ALR ) (the "Company") ... each of its consent solicitations commenced on May 31, ... the "Proposed Modifications") governing its 9.0% Senior Subordinated Notes ... due 2018 (the "8.625% Notes") and 7.875% Senior Notes ...
Cached Medicine Technology:
(Date:7/11/2014)... Europe Well Intervention Market report defines and segments the well ... The well intervention services market in Europe is estimated to ... by 2018, at a CAGR of 7% from 2013 to ... Intervention Market report, to get an idea of the in-depth ... in the Europe well intervention market, and is supported by ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
(Date:7/11/2014)... 2014 Biostimulants are widely applied in ... and ornamentals. These also help turf and ornamentals in ... roots. Turf, ornamentals, and flowers appear healthy and strong ... has increased from the last few years. The most ... is Europe, with around 40% share in 2013, and ...
(Date:7/11/2014)... 2014) Obese and overweight firefighters are not ... providers, according to new research from The University ... , National guidelines state that health care professionals ... maintaining a healthy weight. Firefighters have high rates ... cause of line-of-duty deaths in firefighters. This study ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... innovative approach to treating neonatal feeding problems at Nationwide ... feed orally to be discharged earlier and without feeding ... According to American Academy of Pediatrics guidelines, in ... hospital, they must establish safe oral feeding methods. The ...
... This press release is available in German . ... the biggest risk factors for the development of gastric cancer, the ... biologists from the University of Zurich have now identified a mechanism ... gastric mucosa and sets them up for malignant transformation. Gastric ...
... -- Doctors have been prescribing codeine for postpartum pain management ... to breastfeed while taking the opioid. But the death ... many health care providers questioning the safety of the drug ... risks, some doctors have begun the practice of prescribing oxycodone ...
... HealthDay Reporter , MONDAY, Sept. 5 (HealthDay News) -- Living ... as much as 80 percent, researchers from the U.S. National ... diet, exercise, smoking and drinking have an impact on whether ... each individual factor affects the risk had been unclear. ...
... 6 (HealthDay News) -- There,s no link between menopause ... a study that challenges a long-held medical belief that ... menopause. Aging alone, not the hormonal impact of ... women, according to the Johns Hopkins researchers. The ...
... Sept. 6 (HealthDay News) -- Some children, especially those ... the hospital, a new study finds. Acetaminophen, albuterol ... hospitalized children, the researchers said. They also found an ... of drugs given to children. On the first ...
Cached Medicine News:Health News:Neonatal and infant feeding disorders program saves infants from lifetime of feeding tubes 2Health News:Stomach bacterium damages human DNA 2Health News:Mother's postpartum oxycodone use: No safer for breastfed infants than codeine 2Health News:Healthy Living Can Cut Chances of Developing Diabetes 2Health News:Aging, Not Menopause, Raises Women's Heart Risks, Study Finds 2Health News:Hospitalized Kids May Receive Up to 35 Meds a Week 2
... Beta 200 ophthalmoscope, ... glare-free direct ophthalmoscope. Heine's ... patent #4,963,014) along with ... construction, make the Beta ...
... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...
... Beta 200S is the first ... combination of patented aspherical optics ... range of corrective lenses from ... single diopter steps. A perfectly-focused ...
With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....
Medicine Products: